<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649764</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0665</org_study_id>
    <secondary_id>NCI-2016-00225</secondary_id>
    <secondary_id>2015-0665</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02649764</nct_id>
  </id_info>
  <brief_title>Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and determine the best dose of prexasertib&#xD;
      (LY2606368) when given together with cytarabine and fludarabine in patients with acute&#xD;
      myeloid leukemia or high-risk myelodysplastic syndrome that has returned after a period of&#xD;
      improvement or no longer responds to treatment. Prexasertib (LY2606368) may stop the growth&#xD;
      of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in&#xD;
      chemotherapy, such as cytarabine and fludarabine, work in different ways to stop the growth&#xD;
      of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping&#xD;
      them from spreading. Giving prexasertib (LY2606368) together with cytarabine and fludarabine&#xD;
      may work better in treating patients with acute myeloid leukemia or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and toxicity profile of combination therapy of prexasertib&#xD;
      (LY2606368), fludarabine and cytarabine in patients with relapsed or refractory (first or&#xD;
      second salvage) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HRMDS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the complete response (CR), CR with incomplete count recovery (CRi),&#xD;
      morphologic leukemia free state (MLFS) and partial response (PR) rates.&#xD;
&#xD;
      II. To determine the duration of response. III. To determine the disease-free survival. IV.&#xD;
      To determine the overall survival with combination therapy of LY2606368, fludarabine and&#xD;
      cytarabine in patients with relapsed or refractory AML/HRMDS.&#xD;
&#xD;
      V. To determine the correlative studies including but not limited to total and phosphor&#xD;
      histone (H2AX), checkpoint kinase-2 (Chk1), checkpoint kinase-2 (Chk2), ras protein specific&#xD;
      guanine nucleotide releasing factor 1 (Cdc25), retinoblastoma-associated protein (Rb),&#xD;
      cyclin-dependent kinase (CDK), protein kinase B (AKT) in AML cells by flow cytometry and/or&#xD;
      Western blot.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of prexasertib (LY2606368).&#xD;
&#xD;
      Patients =/&lt; 65 years of age: receive fludarabine intravenously (IV) over approximately 2&#xD;
      hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV&#xD;
      over approximately 2 hours on days 1, 3, and 4 or on days 1-4.&#xD;
&#xD;
      Patients &gt; 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3,&#xD;
      cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2&#xD;
      hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days&#xD;
      for up to 5 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients in remission who do not start new treatment are&#xD;
      followed up every 2-3 months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities of prexasertib in combination with cytarabine and fludarabine</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates (complete response [CR], CR with incomplete count recovery [CRi], morphologic leukemia free state [MLFS], and partial response [PR])</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and phosphorylated biomarker levels in acute myeloid leukemia cells</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measured by flow cytometry and/or Western blot.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent High Risk Myelodysplastic Syndrome</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory High Risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (fludarabine phosphate, cytarabine, prexasertib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients =/&lt; 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients &gt; 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (fludarabine phosphate, cytarabine, prexasertib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (fludarabine phosphate, cytarabine, prexasertib)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (fludarabine phosphate, cytarabine, prexasertib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prexasertib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (fludarabine phosphate, cytarabine, prexasertib)</arm_group_label>
    <other_name>LY2606368</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with histologically or cytologically confirmed relapsed or refractory&#xD;
             acute myeloid leukemia (AML) (except acute promyelocytic leukemia) or relapsed or&#xD;
             refractory high-risk myelodysplastic syndrome (HRMDS) (intermediate 2 [Int-2] or&#xD;
             higher risk by International Prognostic Scoring System [IPSS]); patients with chronic&#xD;
             myelomonocytic leukemia (CMML) can be enrolled if they can be classified as HRMDS&#xD;
             using MDS criteria; patients should not have received more than one salvage therapy;&#xD;
             second induction regimen or stem cell transplant in remission will be considered&#xD;
             salvage therapy; refractory subjects, up to second consecutive salvage&#xD;
&#xD;
          -  Patients must have a performance status of 0-2 (Eastern Cooperative Oncology Group&#xD;
             [ECOG] scale)&#xD;
&#xD;
          -  Serum creatinine less than or equal to 1.3 mg/dL and/or creatinine clearance &gt; 40&#xD;
             mL/min&#xD;
&#xD;
          -  Bilirubin less than or equal to 1.5 mg/dl (unless due to Gilbert's syndrome)&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT)/aspartate transaminase (AST) or serum&#xD;
             glutamate pyruvate transaminase (SGPT)/alanine transferase (ALT) less than or equal to&#xD;
             2.5 X the upper limit of normal (ULN) for the reference lab&#xD;
&#xD;
          -  Patients must have normal cardiac ejection fraction (left ventricular ejection&#xD;
             fraction [LVEF] &gt;/= 45%)&#xD;
&#xD;
          -  Corrected QT (QTc) interval =/&lt; 470 msecs, no familial history of QTc prolongation or&#xD;
             ventricular arrhythmias&#xD;
&#xD;
          -  Female patients must not be pregnant or lactating; female patients of childbearing&#xD;
             potential (including those &lt; 1 year post-menopausal) and male patients must agree to&#xD;
             use contraception&#xD;
&#xD;
          -  Patients who have received prior stem cell transplantation will be allowed to enroll&#xD;
             as long as prior transplantation has been at least 3 months before enrollment in the&#xD;
             trial and any transplant related toxicities have subsided to grade 1 or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have untreated or uncontrolled life-threatening infection&#xD;
&#xD;
          -  Patients must not have been treated with CHK1/2 inhibitors&#xD;
&#xD;
          -  Patients must not have received chemotherapy and/or radiation therapy within 2 weeks&#xD;
             of start of protocol treatment; hydroxyurea is allowed up to 48 hours prior to&#xD;
             starting therapy in the setting of rapidly proliferating disease&#xD;
&#xD;
          -  Patients must not have received an investigational anti-cancer drug within two weeks&#xD;
             of start of protocol treatment&#xD;
&#xD;
          -  Patients must not have active central nervous system leukemia; patients with history&#xD;
             of central nervous system (CNS) leukemia with no evidence of active CNS disease may be&#xD;
             enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement&#xD;
             with leukemia is allowed with approval from the study supporter&#xD;
&#xD;
          -  Patients must not have significant cardiac co-morbidity including: history of acute&#xD;
             coronary syndromes (including myocardial infarction and unstable angina) within 12&#xD;
             months; coronary angioplasty or stenting within 6 months; history or evidence of&#xD;
             current &gt;/= class III congestive heart failure as defined by the New York Heart&#xD;
             Association (NYHA); patients with intra-cardiac defibrillators or permanent pacemakers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

